Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9700301 | 0.78 | L3MBTL1 (0.84) | CYP1A2CYP2D6CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL14559935 | 0.78 | KDM4E (0.55) | CYP1A2CYP2D6CYP2C19ALDH1A1GAA | |
| SCHEMBL6298943 | 0.77 | CTDSP1 (0.49) | ALDH1A1GAAL3MBTL1KMT2AMAPT | |
| SCHEMBL1341846 | 0.76 | RAB9A (0.66) | ALDH1A1L3MBTL1NPC1RAB9ARECQL | |
| SCHEMBL1852361 | 0.75 | CYP2D6 (0.88) | CYP1A2CYP2D6CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL30196559 | 0.74 | L3MBTL1 (0.62) | ALDH1A1L3MBTL1NPC1RAB9ARECQL | |
| SCHEMBL10453566 | 0.74 | L3MBTL1 (0.62) | ALDH1A1L3MBTL1NPC1RAB9ARECQL | |
| SCHEMBL8682230 | 0.74 | RAB9A (0.62) | ALDH1A1L3MBTL1NPC1RAB9ARECQL | |
| SCHEMBL8682233 | 0.74 | RAB9A (0.62) | ALDH1A1L3MBTL1NPC1RAB9ARECQL | |
| SCHEMBL4701680 | 0.73 | ALDH1A1 (0.56) | CYP1A2CYP2D6CYP2C19ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933390-B2 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | WARNER-LAMBERT COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040249185-A1 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | BARTH HUBERT (DE) | 2004-12-09 | — | — | US | disclosed |
| US-6774242-B1 | REACTING WITH INDOLE IN APROTIC SOLVENT | GOEDECKE GMBH (DE) | 2004-08-10 | — | — | US | disclosed |
| EP-1165512-A2 | METHOD FOR ARYLATING AZA-HETEROCYCLES WITH ACTIVATED AROMATIC COMPOUNDS IN THE PRESENCE OF CESIUM CARBONATE | GÖDECKE GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059883-A2 | METHOD FOR PRODUCING N-ARYL-AZA-HETEROCYCLES IN THE PRESENCE OF CESIUM CARBONATE | Gödecke GmbH (DE) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249185-A1 | Process for the arylation of aza-heterocycles with activated aromatics in presence of caesium carbonate | AZI2, KCNH1, CA7 | CYP1A2 30/4885CYP2D6 442/4885CYP2C19 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.